) Trial
Summary-Oral anticoagulants are indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation at risk of stroke. However, the risks and benefits of oral anticoagulants are affected by the addition of antiplatelet drugs, which are commonly needed by these patients for concurrent conditions like coronary artery disease. In this study, we tried to quantify the impact of concomitant antiplatelets on the relative efficacy and safety of dabigatran etexilate (DE) and warfarin in patients with atrial fibrillation. Our results showed that, whether or not patients were on antiplatelet agents, DE given at 150 mg BID reduced stroke and systemic embolism to a greater extent than warfarin, with no increase in the rate of major bleeding. In contrast, DE given at 110 mg BID reduced stroke and systemic embolism to the same extent as warfarin, but with substantially lower rates of major bleeds, irrespective of whether patients were on other antiplatelet drugs or not. Addition of antiplatelet agents was associated with higher risks of bleeding with all the oral anticoagulants in our study. The relative increase in the risk of major bleed was 1.6-fold on a single antiplatelet and 2.3-fold on double antiplatelets. However, the absolute risk of bleeding was lowest on DE given at 110 mg BID. Therefore, in patients needing concomitant antiplatelets, DE has the advantage of 2 dose options: one that maximizes the effectiveness (DE given at 150 mg BID) and another that maximizes safety (DE given at 110 mg BID). Clinicians and patients can select the most appropriate dose to use, depending on the inherent risks for stroke and systemic embolism or hemorrhage of each patient.
Conclusions-Concomitant antiplatelet drugs appeared to increase the risk for major bleeding in RE-LY without affecting the advantages of dabigatran over warfarin. Choosing between DE110 and DE150 requires a careful assessment of characteristics that influence the balance between benefit and harm. Summary-Outpatient cardiac rehabilitation (CR) is a highly effective but significantly underutilized intervention for patients after an acute myocardial infarction, percutaneous coronary intervention, or cardiac surgery. The mortality reduction from CR is similar to that seen with statin medications (range 20% to 35%), yet only ≈30% of eligible patients participate in CR. National organizations, including the American Heart Association, have called for improvement of this important quality gap. One contributing modifiable factor may be the timing of the first appointment for CR. Recent retrospective studies have suggested that for each day of delay between hospital discharge and CR orientation, there is a 1% loss in CR participation. We prospectively randomized 148 patients to receive either an early or standard appointment to CR. Attendance occurred at a median of 8 versus 42 days per group, respectively. We found a significant 18% absolute and 56% relative improvement in attendance at orientation in the early group. Although the effects of an early appointment were limited to attendance at orientation, this technique was simple, safe, and was easily incorporated into the referral routine. Consequently, when coupled with other known effective techniques (automatic-referral and liaison-facilitated referral), an early appointment could potentially increase patient participation in CR and reduce the size of this important quality gap in the secondary prevention of heart disease.
Conclusions-Early appointments for CR significantly improve attendance at orientation. This simple technique could potentially increase initial CR participation nationwide. Summary-Atherosclerosis in an inflammatory condition, and biomarkers of inflammation including CRP, IL-6, and fibrinogen associate with increased vascular risk. However, whether inhibiting inflammation will reduce vascular events is uncertain. One promising anti-inflammatory approach with potential relevance for cardiovascular disease is inhibition of the proinflammatory cytokine IL-1, particularly the IL-1β isoform that is secreted and acts locally but that also induces systemic effects. In a phase IIb randomized trial conducted among high-risk diabetic patients comparing placebo with canakinumab, a monoclonal antibody targeting IL-1β, we observed statistically significant dose-dependent reductions in all 3 of these inflammatory biomarkers without major effect on LDL-C or HDL-C. There were no differences in clinical adverse events e142 Circulation
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between active and placebo patients, although a small increase in triglycerides was observed at higher canakinumab doses. These phase II trial data support the use of canakinumab as a potential therapeutic method to test directly the inflammatory hypothesis of atherosclerosis. Indeed, in part on the basis of these data, a largescale multinational hard outcomes trial, CANTOS, is being conducted that will address directly whether inhibition of IL-1β with canakinumab can reduce recurrent vascular event rates in a highrisk secondary prevention population.
Conclusions-Canakinumab, a human monoclonal antibody that neutralizes interleukin-1β, significantly reduces inflammation without major effect on low-density lipoprotein cholesterol or highdensity lipoprotein cholesterol. These phase II trial data support the use of canakinumab as a potential therapeutic method to test directly the inflammatory hypothesis of atherosclerosis. Summary-Heterozygous familial hypercholesterolemia is a common genetic disorder that leads to premature coronary artery disease. Despite aggressive lipid-lowering therapy, many patients with heterozygous familial hypercholesterolemia fail to achieve optimal low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in patients with heterozygous familial hypercholesterolemia with coronary artery disease who were already on maximally tolerated lipid-lowering therapy and had LDL-C >2.6 mmol/L (100 mg/ dL). The phase 2, double-blind, placebo-controlled trial randomized 124 patients (41 placebo, 83 mipomersen) to weekly subcutaneous mipomersen 200 mg or placebo (2:1) for 26 weeks. The primary end point was percent change in LDL-C from baseline at week 28. Safety assessments included adverse events, laboratory tests, and MRI assessment of hepatic fat. Mean LDL-C decreased 28.0% with mipomersen compared with a 5.2% increase with placebo (P<0.001), and 45.1% compared with 4.9% achieved LDL-C <2.6 mmol/L (100 mg/dL), respectively. Mipomersen significantly (P<0.001) reduced apolipoprotein B (−26.3%) and lipoprotein(a) (−21.1%) compared with placebo. More frequent and severe injection site reactions occurred with mipomersen, and 5 mipomersen-treated patients (6%) had 2 consecutive alanine aminotransferase levels ≥3 times the upper limit of normal at least 7 days apart; none were associated with significant bilirubin increases. Hepatic fat content increased a median of 4.9% with mipomersen versus 0.4% with placebo (P<0.001). The clinical implications of such increases in hepatic fat and transaminase elevations are unclear and must be elucidated in longer-term studies. We conclude that mipomersen is effective to further reduce apolipoprotein B-containing lipoproteins, including LDL and lipoprotein(a), in patients with heterozygous familial hypercholesterolemia with coronary artery disease on statins and other lipid-lowering therapy. =0.65). The degree of algorithmconsistent warfarin dosing accounted for a majority of the TTR variation between centers and countries. Each 10% increase in center algorithm-consistent dosing independently predicted a 6.12% increase in TTR (95% confidence interval, 5.65-6.59), and an 8% decrease in rate of the composite clinical outcome (hazard ratio, 0.92; 95% confidence interval, 0.85-1.00). In summary, warfarin dosing practice that does not change the dose when the INR is in range, and that makes relatively small (10% to 15%) weekly dose adjustments when the INR is out of range, is associated with improved TTR and clinical outcomes. Systems that implement algorithm-based dosing for patients with atrial fibrillation on warfarin could potentially improve outcomes on a global scale, especially in centers and countries with suboptimal INR control.
Conclusions-Mipomersen
Conclusions-Adherence, intentional or not, to a simple warfarin dosing algorithm predicts improved TTR and accounts for considerable TTR variation between centers and countries. Systems facilitating algorithm-based warfarin dosing could optimize anticoagulation quality and improve clinical outcomes in atrial fibrillation on a global scale.
5

Predictors of Early and Late Enrollment in Cardiac Rehabilitation, Among Those Referred, After Acute Myocardial Infarction
Summary-Cardiac rehabilitation (CR) is a key component of the comprehensive care of acute myocardial infarction (AMI) patients and is a Class I recommendation after AMI. While improving the use of CR has been a longstanding goal for quality improvement, there remains a gap between referral to CR and subsequent participation. In our study, despite a high CR referral rate of 66% post-AMI, only 29% referred patients participated in CR at 1-month and less than half participated at 6-months after AMI, making it an important quality improvement target. Several patient-oriented and medical factors affect early and late CR enrollment even after receiving CR referral after AMI. Women, the uninsured, and patients with hypertension, peripheral arterial disease, lower physical function, and prior percutaneous coronary intervention are less likely to participate at 1-month while non-Caucasians, older individuals, smokers and individuals with economic burden were less likely to participate at 6-months after AMI. These individuals represent populations at
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significantly increased cardiovascular risk who may benefit from the more intense secondary prevention services provided in CR.
Since CR is associated with beneficial changes in cardiovascular risk factors and better outcomes, more aggressive efforts to increase CR participation after AMI are needed. There are still substantial gender and socio-economic disparities in CR use that will require additional interventions to overcome. While creating a performance measurement for referral is an important first step, creating a second measure to examine actual participation might be a successful adjunct to insure participation if proper denominator specifications can be created.
Conclusions-Among patients referred for CR post-AMI, participation remains low both at 1 and 6 months after AMI. Because CR is associated with beneficial changes in cardiovascular risk factors and better outcomes after AMI, more aggressive efforts are needed to increase CR participation after referral. Summary-High level of physical fitness and regular exercise are closely related to cardiovascular health and reduced risk of cardiovascular disease and mortality. Aerobic exercise is therefore strongly recommended for patients with coronary heart disease. Exercise performed at higher relative intensities has been found to elicit greater increase in aerobic capacity and greater cardioprotective effects than exercise at moderate intensities. Despite that higher levels of physical activity are found to reduce cardiovascular events, it is advocated that vigorous activity could also acutely and transiently increase the risk of sudden cardiac events in susceptible persons. We therefore studied the risk of cardiovascular events during organized highintensity interval exercise training and moderate-intensity training among 4846 coronary heart disease patients in 4 Norwegian cardiac rehabilitation centers. The event rate after patients were exposed to both types of exercise training was low. In a total of 175 820 exercise training hours where all patient performed both types of training, we found 1 fatal cardiac arrest during moderate-intensity exercise (129 456 exercise hours) and 2 nonfatal cardiac arrests during highintensity interval exercise (46 364 exercise hours). There were no myocardial infarctions in the data material. Because the number of high-intensity training hours was 36% of the number of moderateintensity hours, the rates of complications to the number of patientexercise hours were 1 per 129 456 of moderate-intensity exercise and 1 per 23 182 of high-intensity exercise. We believe that our study provides needed knowledge about the risk of high-intensity exercise training for patients undergoing secondary cardiac rehabilitation.
Conclusions-
The results of the current study indicate that the risk of a cardiovascular event is low after both high-intensity exercise and moderate-intensity exercise in a cardiovascular rehabilitation setting. Considering the significant cardiovascular adaptations associated with high-intensity exercise, such exercise should be considered among patients with coronary heart disease. In the propensity-matched cohort, CR remained associated with improved mortality (hazard ratio, 0.67; 95% confidence interval, 0.54-0.81). These findings confirm reduced mortality in association with CR as seen in other studies, but in a larger, better-described population, while also newly demonstrating a significant reduction in hospitalization. Given the increasing number of subjects surviving initial cardiac events, the importance of completing a CR program to reduce future risk of hospitalization and mortality needs to be recognized. 
Conclusions-Among
Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients
Summary-It remains uncertain whether the influenza vaccine is associated with a reduced risk of vascular events, despite at least 10 observational studies and 3 small randomized controlled trials investigating this association. The existing observational studies were limited by small size, involved only a single influenza season, and/or were at risk of significant bias resulting from study design and the presence of confounding. The 3 randomized controlled trials were small with few event rates, precluding any definitive conclusions. We therefore performed an observational study using data from a large multinational trial of patients at high risk for vascular events involving 31 546 participants from 733 centers in 40 countries. Although initial analyses suggest that influenza vaccination was associated with a reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, detailed sensitivity analyses revealed that evidence of risk of confounding bias remained. A randomized trial is needed to definitively address this question.
Conclusions-Although initial analyses suggest that influenza vaccination was associated with reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, sensitivity analyses revealed that risk of bias remained. A randomized trial is needed to definitively address this question.
12
Determinants of Residual Risk in Secondary Prevention Patients Treated With High-Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study
Summary-Cardiovascular risk among statin-treated individuals remains high and has been called residual risk, but the mechanisms underlying this residual risk are uncertain. Hence, we aimed to identify determinants of this risk above and beyond lipid-related risk factors in a secondary prevention population that achieved low low-density lipoprotein cholesterol targets. The study population comprised 9251 coronary patients with low-density lipoprotein cholesterol <130 mg/dL randomized to double-blind atorvastatin 10 or 80 mg/d in the Treating to New Targets (TNT) study who had complete on-treatment 1-year lipid data. Median follow-up was 4.9 years. The primary end point was major cardiovascular events (n=729): coronary death, nonfatal myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. Multivariable determinants of increased risk were older age, increased body mass index, male sex, hypertension, diabetes mellitus, baseline apolipoprotein B and blood urea nitrogen, current smoking, prior cardiovascular disease, and calcium channel blocker use. Determinants of decreased risk were high-dose statin, aspirin use, and baseline apolipoprotein A-I. These known baseline clinical and lipid-related variables performed moderately well in discriminating future cases from noncases. On-treatment 1-year levels of lipids and apolipoproteins were not selected into the multivariable model because they were not associated with risk after baseline apolipoproteins and clinical risk factors were taken into account. In sum, residual risk among statin-allocated coronary patients was related to baseline lipid-related and nonlipid risk factors. Thus, a multifaceted secondary prevention approach targeting modifiable risk factors should be underscored as the cornerstone of optimal residual risk assessment and prevention.
Conclusions-Determinants of residual risk in statin-treated secondary prevention patients included lipid-related and nonlipid factors such as baseline apolipoproteins, increased body mass index, smoking, hypertension, and diabetes mellitus. A multifaceted prevention approach should be underscored to address this risk.
13
Short-Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial
Summary-This study focusing on 2013 patients undergoing coronary stent implantation who received bare-metal, zotarolimuseluting, paclitaxel-eluting, or everolimus-eluting stent implantation and were subsequently allocated to up to 6 months versus 24 months of clopidogrel therapy in addition to aspirin failed to show the anticipated superiority of long-term duration of dual-antiplatelet therapy in terms of a lower composite ischemic end point of overall death, myocardial infarction, or cerebrovascular accidents. The cumulative risk of the primary outcome at 2 years was 10.1% with 24-month dual-antiplatelet therapy compared with 10.0% with 6-month dual-antiplatelet therapy (hazard ratio, 0.98; 95% confidence interval, 0.74-1.29; P=0.91). The individual risks of death, myocardial infarction, cerebrovascular accident, or stent thrombosis did not differ between the study groups; however, there was a consistently greater risk of hemorrhage in the 24-month clopidogrel group according to all prespecified bleeding definitions, including the recently proposed Bleeding Academic Research Consortium classification. Two Korean studies have also previously reported a lack of benefit of either 12 or 24 months of clopidogrel therapy over 6 or 12 months of therapy, respectively. Therefore, altogether, the available evidence does not support the concept that the longer the duration of clopidogrel therapy after drug-eluting stent implantation, the better the outcomes. On the contrary, this study identifies the potential for harm with respect to major bleeding associated with prolonged use of dual-antiplatelet therapy.
Conclusions-A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or baremetal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident.
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Global Variation in the Prevalence of Elevated Cholesterol in Outpatients With Established Vascular Disease or 3 Cardiovascular Risk Factors According to National Indices of Economic Development and Health System Performance
Summary-The exponential rise in cardiovascular disease over the past decade has placed a tremendous burden on the health and economic development of countries worldwide, with unprecedented demands for an effective response from governments and other stakeholders in global health. From a large, multinational registry of outpatients with established cardiovascular disease or ≥3 risk factors, we used data from 53 570 individuals from 36 countries to examine the relationship between country-level economic and health system factors and the risk of elevated cholesterol (total cholesterol levels >200 mg/dL). The analysis was performed separately for patients with versus without previous history of hyperlipidemia; a higher proportion of the total variability in elevated cholesterol was at the country level for patients with (12.1%) versus without (7.4%) history of hyperlipidemia. Among patients with history of hyperlipidemia, after adjusting for patient-level demographic and clinical characteristics and average fat consumption at the country level, countries in the highest tertile of gross national income or World Health Organization index of health system achievement were found to have significantly lower odds of elevated cholesterol than those in each of the lower 2 tertiles, and the odds of elevated cholesterol was higher for countries in higher versus lower tertile of out-of-pocket health expenditures. No significant associations between countrylevel factors and elevated cholesterol were found for patients without history of hyperlipidemia. These results support the need for strengthening efforts toward effective cardiovascular disease prevention and control and may provide insight for health policy setting at the national level.
Conclusions-Global variations in the prevalence of elevated cholesterol among patients with history of hyperlipidemia are associated with country-level economic development and health system indices. These results support the need for strengthening efforts toward effective cardiovascular disease prevention and control and may provide insight for health policy setting at the national level. Summary-Sudden cardiac death is preventable with implantable cardioverter-defibrillators. These devices can now be placed not only in patients who have had a sustained arrhythmia, but also in those deemed high risk for whom a mortality benefit can also be derived. Unfortunately, a sizable percentage of patients who receive these devices may have frequent or inappropriate shock therapy. We have learned that these events are psychologically devastating, cause frequent hospitalizations, and predispose to morbid and mortal events. Although antiarrhythmic drugs are frequently used to prevent frequent device discharges, no drug has gained US regulatory approval for this indication. On the basis of favorable data obtained in a small phase IIA trial, we studied the efficacy and safety of celivarone, a novel benzofuran derivative and congener of amiodarone and dronedarone, for the prevention of device activation and sudden death. In a multinational, multicenter, prospective, double-blind, randomized parallel-group trial, we compared 3 doses of celivarone with placebo and included an amiodarone calibrator arm to confirm the adequacy of the design and the study population. Although it proved to be well tolerated and safe, we found no significant benefit for celivarone for this indication at any dose. Amiodarone, as expected, reduced device activations, including shocks, but was associated with a higher mortality than placebo, whereas celivarone was mortality neutral. The search for drugs to prevent device activation and death in implantable cardioverter-defibrillator patients will continue. The Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator Interventions or Death (ALPHEE), although a negative trial, provides a precedent for the study of new drugs for ventricular indications.
Conclusions-Celivarone was not effective for the prevention of ICD interventions or sudden death.
20
Statin Use in Outpatients With Obstructive Coronary Artery Disease
Summary-In the large, contemporary Practice Innovation and Clinical Excellence (PINNACLE) outpatient registry, we examined rates of guideline-based treatment with lipid-lowering therapy in 38 775 patients with obstructive coronary artery disease (defined as history of myocardial infarction or prior coronary revascularization) and without contraindications to statin therapy. We found that 78% of patients were receiving guideline-based treatment with statins, 5% were treated only with nonstatin lipid-lowering medications, and 17% of patients were not treated with any lipid-lowering therapy at all. Among untreated patients, half had low-density lipoprotein cholesterol (LDL-C) levels ≥100 mg/dL. Despite multiple clinical trials that have shown that statin therapy reduces cardiovascular morbidity and mortality in this population, a substantial number of highrisk patients remained untreated with statins despite elevated levels of LDL-C. We also found that half of untreated patients had LDL-C levels <100 mg/dL. Although appearing to have reached established LDL-C treatment "targets" for secondary prevention, these patients were not receiving guideline-based care because they were not treated with any lipid-lowering therapy. Our data suggest that some physicians may be making decisions about lipid management for these patients on the basis of baseline LDL-C levels alone rather than on the basis of clinical trial evidence, which has demonstrated a consistent benefit with statin therapy in secondary prevention regardless of baseline LDL-C levels. These findings highlight important opportunities to improve the use of statin therapy in outpatients at high risk for recurrent cardiovascular events.
Conclusions-Despite robust clinical trial evidence, a substantial number of patients with obstructive CAD remain untreated with statins. A small proportion were treated with nonstatin therapy, and 1 in 6 patients was simply untreated; half of the untreated patients had low-density lipoprotein cholesterol values <100 mg/dL. These findings illustrate important opportunities to improve lipid management in outpatients with obstructive CAD.
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Impact of Exercise on Heart Rate Recovery
Summary-An abnormal heart rate recovery has been shown to have prognostic value in multiple patient populations and to give additional prognostic information independently of functional capacity, ischemia, or coronary artery disease. However, whether abnormal heart rate recovery can be reversed is controversial. Because exercise has been shown to improve autonomic tone, it stands to reason that perhaps exercise training can improve abnormal heart rate recovery.
To date, studies of cardiac rehabilitation on heart rate recovery have been limited by small sample size. In our study of 1070 consecutive patients who underwent symptom-limited exercise ECG testing before and after completion of phase 2 cardiac rehabilitation, we found that heart rate recovery improved with exercise training. There was a strong association of abnormal heart rate recovery at exit of cardiac rehabilitation with all-cause mortality. Patients who had abnormal heart rate recovery at baseline but had normalized heart rate recovery at exit had survival rates similar to those with normal heart rate recovery. The beneficial autonomic effect of exercise training, specifically enhanced vagal reactivation, suggests a plausible explanation as to why exercise training may favorably improve heart rate recovery.
Conclusions-Heart rate recovery (HRR) improved after phase 2 cardiac rehabilitation in the overall cohort. There was a strong association of abnormal HRR at exit with all-cause mortality.
Patients with abnormal HRR at baseline who normalized HRR with exercise had a mortality similar to that of individuals with baseline normal HRR. Summary-Type 2 diabetes mellitus is associated with a 2-to 4-fold increase in the incidence and prevalence of coronary artery disease. Comparable increases occur also with respect to cardiovascular events including death, myocardial infarction, and stroke. Insulin resistance has been implicated strongly in accelerating the pathogenesis of coronary artery disease. Two mechanisms potentially linking insulin resistance to poor prognosis include constraint of fibrinolysis and intensification of inflammation. In this study, 2368 patients with type 2 diabetes mellitus and clinically stable angiographically documented coronary artery disease were treated with either an insulin-sensitizing or insulin-providing strategy for glycemic control targeting hemoglobin A 1c to <7.0%. Changes in biomarker profiles during the targeted 5 years of follow-up were consistent with reduction of constraints on fibrinolysis and diminution of the intensity of the inflammatory state with the insulin-sensitizing strategy. These changes were not seen with the insulin-providing strategy. On the contrary, the insulin-providing strategy was associated with an apparently increased constraint of fibrinolysis. Thus, the use of insulin-sensitizing drugs for glycemic control may confer benefit with respect to the balance between fibrinolysis and thrombosis, favoring fibrinolysis in patients with type 2 diabetes mellitus.
Conclusions-The insulin-sensitizing treatment strategy led to changes in biomarker profiles indicative of decreased insulin resistance, an altered balance between thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic inflammatory state, factors that have been associated with cardiovascular risk. 
Association Between Myocardial Infarction and Fractures: An Emerging Phenomenon
Summary-Accumulating evidence links atherosclerotic disease to osteoporosis, but the specific association between myocardial infarction (MI) and fractures has rarely been studied, and temporal trends have not been evaluated. Using data spanning 30 years (1979-2009), originating from carefully characterized cohorts (3321 consecutive incident MI patients and 3321 community-based non-MI control subjects individually matched on age, sex, and year of onset) with complete ascertainment of fractures, we detected a steady increase in osteoporotic fracture risk after MI, a novel finding not observed in the general population. This alarming temporal trend was robust across patient groups and fracture sites and is consistent with the displacement of post-MI outcomes toward noncardiovascular events. Thus, fracture prevention initiatives after MI are likely warranted, particularly among high-risk patient groups, such as the elderly, women, and those with prior fracture and/or coexisting illnesses. Furthermore, frailty symptoms, which are frequently overlooked in the traditional disease-specific model of cardiac care applied to MI patients, should be assessed and treated. Participation in secondary prevention programs should be aggressively pursued given the beneficial role of physical activity for the prevention of bone loss and falls, crucial elements in fracture prevention.
Conclusions-Over the past decades, the association between MI and osteoporotic fractures increased steadily. The trend is consistent with the displacement of post-MI outcomes toward noncardiovascular events, highlighting the need for comprehensive prevention strategies to accommodate the changing epidemiology of MI.
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Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004
Summary-Cardiovascular disease remains a major cause of morbidity and mortality in the United States. Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis that confers a significantly increased risk of myocardial infarction, stroke, and death. Whether cardiovascular risk can be reduced by implementation of secondary prevention therapies (such as antiplatelet therapy, statins, or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) in individuals with PAD identified by a screening ankle-brachial index measurement is unknown. Using data from the National Health and Nutrition Examination Survey (NHANES), we demonstrate that millions of high-risk US adults with PAD (anklebrachial index ≤0.90) were not receiving guideline-recommended secondary prevention therapies. All-cause mortality was significantly higher in individuals with PAD, including those without previously recognized cardiovascular disease. Furthermore, treatment with multiple secondary prevention therapies was associated with significantly reduced risk of all-cause mortality in this population. Given the conflicting literature about the use of secondary prevention therapies, aspirin in particular, in patients with PAD, these observational findings underscore the importance of a large-scale clinical trial to determine whether implementation of multiple secondary prevention therapies specifically in high-risk individuals identified by ankle-brachial index screening as having PAD can indeed reduce cardiovascular morbidity and mortality.
Conclusions-Millions of US adults with PAD are not receiving secondary prevention therapies. Treatment with multiple therapies is associated with reduced all-cause mortality.
25
Impact of Cardiac Rehabilitation on Mortality and Cardiovascular Events After Percutaneous Coronary Intervention in the Community
Summary-Although participation in cardiac rehabilitation (CR) has been associated with reduced mortality after myocardial infarction, less is known about its impact after percutaneous coronary intervention (PCI). We studied the association between CR participation and outcomes in 2395 consecutive patients who underwent PCI in Olmsted County, Minnesota, from 1994 to 2008. Overall participation in CR was 40% after PCI over the length of our study. Using 3 different analytic techniques aimed at reducing potential sources of bias, we found that CR participation was associated with a 45% to 47% reduction in 5-year all-cause mortality rate compared with nonparticipation. These findings provide support for national guidelines that recommend CR for patients after PCI, and for the decision in 2006 by the Centers for Medicare and Medicaid Services to include PCI as a covered indication for CR services. Cardiac rehabilitation participation should be encouraged as part of an evidence-based secondary prevention plan for patients who have undergone PCI.
Conclusions-We found that CR participation after percutaneous coronary intervention was associated with a significant reduction in mortality rates. These findings add support to published clinical practice guidelines, performance measures, and insurance coverage policies that recommend CR for patients after percutaneous coronary intervention.
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Declining Stroke and Vascular Event Recurrence Rates in Secondary Prevention Trials Over the Past 50 Years and Consequences for Current Trial Design
Summary-Formal analysis of secondary stroke prevention trials over the last 5 decades confirms that vascular event rates in control arms have declined substantially. Annual recurrent stroke rates in control arms fell from 8.71% in trials launched in the 1960s to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% in the 1990s, and 4.98% in the 2000s. Annual event rates for fatal stroke decreased from 2.87±1.04% in the 1960s to 0.36±0.14% in the 2000s, and those for major vascular events declined from 10.91±1.29% in the 1960s to 6.29±0.68% in the 2000s. Multivariate analysis suggests that increasing antithrombotic use and lower blood pressures were the most important drivers of vascular event rate reduction. The sample size required for adequately powered trials more than doubled during the study period. If a continued linear decline is assumed, the annual recurrent stroke rate in trial control arms in the coming decade is projected to be 2.25%, and control group sample size requirements would increase to 15 983 patients for a trial designed to detect a 20% relative risk reduction in the frequency of recurrent stroke, with 2 years of follow-up, 80% power, and 5% α error. The introduction into clinical practice of successive waves of therapies with proven efficacy in stroke prevention has been notably successful, resulting in a substantial decline in the rate of recurrent vascular events in the control arms of secondary stroke prevention trials. Consequently, trials of new therapies are more arduous, requiring ever larger sample sizes to confirm treatment efficacy, and clinical investigators must cope with the paradox of progress.
Conclusions-Recurrent stroke and vascular event rates have declined substantially over the last 5 decades, with improved blood pressure control and more frequent use of antiplatelet therapy as the leading causes. Considerably larger sample sizes are now needed to demonstrate incremental improvements in medical secondary prevention. Elevations in alanine aminotransferase combined with a rare increase in bilirubin presented potential hepatic safety issues, resulting in termination of development. The lapaquistat experience illustrates the current challenges in lipid-altering drug development.
Conclusions-Squalene synthase inhibition with lapaquistat acetate, alone or in combination with statins, effectively lowered low-density lipoprotein cholesterol in a dose-dependent manner. Elevations in alanine aminotransferase, combined with a rare increase in bilirubin, presented potential hepatic safety issues, resulting in termination of development. The lapaquistat experience illustrates the current challenges in lipid-altering drug development.
28
Particle Traps Prevent Adverse Vascular and Prothrombotic Effects of Diesel Engine Exhaust Inhalation in Men
Summary-There is a robust and consistent association between air pollution and cardiovascular morbidity and mortality. These harmful effects are most strongly associated with exposure to traffic-derived fine particles that predominantly originate from diesel engine exhaust emissions. Using a purpose-built exposure chamber, we have demonstrated previously the adverse vascular and prothrombotic effects of exposure to diesel exhaust in healthy men. In the present study, using complementary and relevant measures of cardiovascular health, we have reconfirmed the adverse effects of exposure to diesel engine exhaust on endothelial function and ex vivo thrombosis. In addition, for the first time, we demonstrate that reducing the particulate component of diesel exhaust with a commercially available particle trap can prevent these detrimental cardiovascular effects. Our study provides support for the application of particle traps to diesel-powered vehicles to reduce urban particulate concentrations and limit a range of adverse cardiovascular effects related to exposure to traffic-derived air pollution.
Conclusions-Exhaust particle traps are a highly efficient method of reducing particle emissions from diesel engines. With a range of surrogate measures, the use of a particle trap prevents several adverse cardiovascular effects of exhaust inhalation in men. Given these beneficial effects on biomarkers of cardiovascular health, the widespread use of particle traps on diesel-powered vehicles may have substantial public health benefits and reduce the burden of cardiovascular disease.
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Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Summary-Kidney transplant recipients experience an excess risk of cardiovascular disease and elevated total homocysteine concentrations. Although observational studies of patients with chronic kidney disease suggest that increased homocysteine is a risk factor for cardiovascular disease, the clinical benefit of lowering total homocysteine levels in kidney transplant recipients is unknown. We randomized 4110 stable kidney transplant recipients to a multivitamin that included either a high dose (n=2056) or low dose (n=2054) of folic acid, vitamin B6, and vitamin B12 to determine whether decreasing total homocysteine concentrations reduced the rate of arteriosclerotic cardiovascular disease outcomes. After a followup of 4.0 years, the high-dose multivitamin reduced homocysteine levels but not the rates of the pooled arteriosclerotic outcome (n=547 total events; hazards ratio Conclusions-Treatment with a high-dose folic acid, B6, and B12 multivitamin in kidney transplant recipients did not reduce a composite cardiovascular disease outcome, all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocysteine level.
30
Incidence of Sudden Cardiac Death in National Collegiate Athletic Association Athletes
Summary-This report more accurately estimates the incidence of sudden cardiac death (SCD) in athletes using improved methodology compared with previous studies. It demonstrates an overall rate of SCD of 1:43 000, with some subpopulations showing a risk of SCD as high as 1:3000. The rate of SCD has been commonly cited as 1:200 000. From a clinical perspective, this is critically important information. The preparticipation examination, or sports physical, is a core part of the practice of sports medicine and primary care physicians alike. The purpose of the preparticipation examination, according to the latest AHA scientific statement, is to identify conditions that may lead to SCD. The current recommendation of the AHA is that this is best done, in the United States, by the use of a directed history and physical examination. There is increasing evidence that this strategy is neither effective nor cost-effective. In other countries, an ECG is a routine part of a sports physical, or in some cases a wellchild visit. The information presented in this report will inform the ongoing discussion about SCD in young people and how best to prevent it. There may be subpopulations of athletes or young people in which screening with an ECG by use of modern interpretation criteria would be highly cost-effective, and others in which it would not. This report will have significant ramifications for clinical practice as we strive to understand how to best use our resources, fulfill the primary objective of the sports physical, prepare for sudden cardiac arrest, and ultimately prevent SCD.
Conclusions-SCD is the leading medical cause of death and death during exercise in NCAA student-athletes. Current methods of data collection underestimate the risk of SCD. Accurate assessment of SCD incidence is necessary to shape appropriate health policy decisions and develop effective strategies for prevention.
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Effects of Optimal Medical Treatment With or Without Coronary Revascularization on Angina and Subsequent Revascularizations in Patients With Type 2 Diabetes Mellitus and Stable Ischemic Heart Disease
Summary-The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial showed that a strategy of prompt coronary revascularization and optimal medical treatment (REV) was not superior to a strategy of optimal medical treatment with the option of subsequent coronary revascularization (MED) in reducing total mortality and the composite of death, myocardial infarction, or stroke in patients with type 2 diabetes mellitus and stable coronary heart disease. However, does the strategy of prompt revascularization compared with the other strategy reduce worsening angina, new angina, and subsequent coronary revascularization? To answer this question, we evaluated the 2364 BARI 2D participants followed up for 5.3 years. At entry in the trial, 1191 were randomized to MED and 1173 to REV preselected in the percutaneous coronary intervention (n=796) and coronary artery bypass graft (n=377) strata. Patients in the coronary artery bypass grafts stratum had more severe coronary disease and were at higher risk than patients in the percutaneous coronary interventions stratum. Compared with the MED strategy, the REV strategy at the 3-year follow-up had a lower rate of worsening angina (8% versus 13%), new angina (37% versus 51%), and subsequent coronary revascularizations (18% versus 33%) and a higher rate of angina-free status (66% versus 58%). Coronary artery bypass graft stratum patients had the greatest benefits from REV. Thus, patients in the REV strategy had less angina and fewer subsequent coronary revascularizations than patients in the MED strategy. The symptomatic benefits were observed particularly for high-risk patients.
Conclusions-In these patients, the REV strategy reduced the occurrence of worsening angina, new angina, and subsequent coronary revascularizations more than the MED strategy. The symptomatic benefits were observed particularly for high-risk patients. Our findings confirm that low-dose ASA and clopidogrel are associated with an increased risk of UGIB in the general population and show that the risk of UGIB is increased further in patients using combination therapies. These factors should be taken into account when assessing the risk-to-benefit ratio of low-dose ASA.
Conclusions-Use of low-dose ASA is associated with an almost 2-fold increase in the risk of UGIB compared with nonuse. This risk is increased further in individuals taking low-dose ASA along with clopidogrel, oral anticoagulants, nonsteroidal anti-inflammatory drugs, or high-dose oral corticosteroids.
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Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide-Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia
Summary-Hypercholesterolemia is associated with impaired vasomotor endothelial function, which is a recognized surrogate marker of outcome. We tested the hypothesis that a novel p38 MAP kinase inhibitor, losmapimod, could improve nitric oxide-mediated responses in such a cohort. We demonstrated for the first time that moderate blockade of this pathway improved endothelial-dependent and -independent nitric oxide-mediated vasodilatation in addition to reducing systemic inflammation, as evidenced by an almost 60% reduction in high-sensitivity C-reactive protein, without alteration in cholesterol levels. Inhibition of p38 may be an attractive target in patients with underlying vascular inflammation.
Conclusions-Losmapimod improves nitric oxide-mediated vasodilatation in hypercholesterolemic patients, which is consistent with findings in previous translational animal models. These data support the hypothesis that attenuating the inflammatory milieu by inhibiting p38 MAPK activity improves NO activity. This suggests p38 MAPK as a novel target for patients with cardiovascular disease.
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Secondary Prevention After Coronary Artery Bypass Graft Surgery: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation Into Practice
Summary-This randomized controlled trial rigorously tests, on a national scale, whether low-intensity continuous quality improvement interventions can be used to speed secondary prevention adherence after coronary artery bypass graft surgery. A total of 458 hospitals participating in the Society of Thoracic Surgeons National Cardiac Database and treating 361 328 patients undergoing isolated coronary artery bypass graft surgery were randomized to either a control or an intervention group. The intervention group received continuous quality improvement materials designed to influence the prescription of the secondary prevention medications at discharge. The primary outcome measure of the study was discharge prescription rates of the targeted secondary prevention medications at intervention versus control sites, assessed by measuring preintervention and postintervention site differences. Prerandomization treatment patterns and baseline data were similar in the control (n=234) and treatment (n=224) groups. Individual medication use and composite adherence increased over 24 months in both groups, with a markedly more rapid rate of adherence uptake among the intervention hospitals and a statistically significant therapy hazard ratio in the intervention versus control group for all recommended secondary prevention medications. Thus, we conclude that provider-led, low-intensity continuous quality improvement efforts can improve the adoption of clinical care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement.
Conclusions-Provider-led, low-intensity continuous quality improvement efforts can improve the adoption of care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement. Summary-Coronary artery bypass grafting (CABG) is an effective treatment for ischemic heart disease, but its long-term results are compromised by the development of saphenous vein graft (SVG) disease. After surgery, a platelet-mediated thickening of the SVG wall occurs, with smooth muscle cell proliferation and extracellular matrix protein synthesis. This process, termed intimal hyperplasia, forms a template for the development of SVG atherosclerosis and eventual occlusion. Clopidogrel has been shown to inhibit intimal hyperplasia in animal studies and therefore may reduce SVG intimal hyperplasia after coronary artery bypass grafting. In the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study, we conducted a double-blind, placebocontrolled trial to evaluate whether the addition of clopidogrel to aspirin inhibits the development of SVG disease. A total of 113 patients undergoing coronary artery bypass grafting with SVGs were randomized to receive either aspirin 162 mg plus clopidogrel 75 mg daily or aspirin 162 mg plus placebo daily for 1 year, followed by SVG intravascular ultrasound and coronary angiography. The primary outcome, SVG intimal area at 1 year, did not differ significantly between the 2 groups (4.1±2.0 versus 4.5±2.1 mm 2 , aspirin-clopidogrel versus aspirin-placebo, P=0.44). Graft patency and freedom from major adverse cardiovascular events also did not significantly differ between the 2 groups. In summary, CASCADE indicated that compared with aspirin monotherapy, the combination of aspirin plus clopidogrel did not significantly reduce SVG intimal hyperplasia 1 year after coronary artery bypass grafting. Newer antiplatelet agents with purported advantages over clopidogrel may constitute important areas for future research to target the inhibition of SVG disease after CABG.
Conclusions-Compared with aspirin monotherapy, the combination of aspirin plus clopidogrel did not significantly reduce the process of SVG intimal hyperplasia 1 year after coronary artery bypass grafting.
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Age-Dependent Effect of β-Blockers in Preventing Vasovagal Syncope
Summary-Syncope affects ≈50% of adults, is the cause of 1% to 2% of emergency room visits, and probably is responsible for $2.4 billion in US healthcare costs yearly. Vasovagal syncope is the most common type and can be provoked by isoproterenol during tilt-table tests. Despite the ability of β-blockers to prevent syncope during tilt-table testing, these drugs failed to reduce syncope in randomized trials. Three observational studies hinted that β-blockers might prevent syncope mainly in older subjects. We assessed whether there was evidence of an age-dependent effect of β-blockers in the randomized Prevention of Syncope Trial and an earlier observational study, by performing a meta-analysis. The estimate of the hazard ratio of β-blockers on syncope for patients aged <42 years was 1.58 (CI, 1.00-2.31) but was 0.52 (CI, 0.27-1.01) for patients aged ≥42 years. In a test of interaction, the 2 age groups differed significantly in response to β-blockers (P=0.007). These results raise the possibility of preventing vasovagal syncope in older patients with β-blockers. Randomized trials that focused on β-blockers in the older population are warranted.
Conclusions-β-blocker treatment may suppress vasovagal syncope in middle-aged patients aged >42 years.
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Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial
Summary-Several post hoc analyses from clinical trials suggest that upstream therapy with angiotensin II receptor blockade (ARB) is beneficial in patients with atrial fibrillation (AF). So far to our knowledge, a proof-of-principle study showing that ARBs have true antiarrhythmic potential has not been published. The ANTIPAF (Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation) trial is the first prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of days with documented episodes of paroxysmal AF) during a 12-month follow-up as the primary study end point. Four hundred twenty-five patients were followed using daily transtelephonic ECG recordings independent of symptoms. The extensive number of 87 818 transtelephonic ECGs were analyzed during follow-up. The primary end point (AF burden) as well as secondary end points were not different in the 2 treatment groups. Thus, 1 year of ARB therapy per se did not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease. In contrast to GISSI-AF and the ACTIVE (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) program, no concomitant use of angiotensin-converting enzyme inhibitors and antiarrhythmic drugs was allowed in ANTIPAF. Therefore, the ANTIPAF study proves that upstream therapy with ARB per se does not reduce the recurrence rate of AF. In the clinical setting, ARB should only be used in patients with AF if these substances are indicated for therapy of concomitant diseases like hypertension and heart failure. September 3, 2013
Conclusions-One year of ARB therapy per se does not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease.
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Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease: Who Is at Risk of Shocks?
Summary-Sudden cardiac death is a major cause of mortality in adults with congenital heart disease (CHD) and might be prevented by implantable cardioverter defibrillator (ICD) therapy. The number of patients with CHD who receive an ICD is steadily increasing. However, in this population, contrary to the patients with ischemic or nonischemic cardiomyopathy, the indication for ICD implantation is poorly defined and little is known about the efficacy of ICD therapy. Therefore, we conducted a multicenter study to determine the long-term outcome of ICD therapy in adults with CHD and developed a simple risk score model for appropriate ICD discharges. Overall, 136 adults with CHD and ICD (mean age ± SD, 41±13 years; 67% male) were identified. The indication for ICD implantation was primary prevention in 50% of patients. Thirty-nine patients (29%) received effective appropriate ICD shocks during a median followup of 4.6 years. Patients with a secondary prevention indication, coronary artery disease (CAD), and symptomatic nonsustained ventricular tachycardias were at highest risk of receiving appropriate shocks. Based on these clinical features, a risk score was developed to evaluate the likelihood of appropriate ICD shocks. The 8-year Kaplan-Meier curve to first appropriate shock was 94%, 57%, and 26% for low-, intermediate-, and high-risk patients, respectively. More important, morbidity was considerable because of the relatively high rate of inappropriate shocks (30%) and implantation-related complications (29%). Therefore, the risk/benefit ratio of ICD therapy should be carefully assessed in individual patients. In patients with supraventricular tachycardias, ablation before ICD implantation should be considered because this reduced the risk of inappropriate shock by 25%. In addition, because the population of adults with CHD is growing and aging, assessment of CAD might be warranted.
Conclusions-Adults with CHD and ICDs receive high rates of appropriate and effective shocks. Patients with secondary prevention indication, coronary artery disease, and symptomatic non-sustained ventricular tachycardia are at highest risk of receiving appropriate ICD shocks. ICD implantation is accompanied by considerable morbidity, including inappropriate shocks and procedure-related complications. 39 
Additional Ablation of Complex Fractionated Atrial Electrograms After Pulmonary Vein Isolation in Patients With Atrial Fibrillation: A Meta-Analysis
Summary-Although proved to be effective in the maintenance of sinus rhythm in patients with atrial fibrillation (AF), pulmonary vein antrum isolation (PVAI), the mainstream catheter ablation of AF, has limited success in eliminating AF, especially in nonparoxysmal AF. The ablation of complex fractionated atrial electrograms (CFAEs) has been proposed as an adjunctive procedure to improve the maintenance of sinus rhythm after PVAI. To quantify the efficacy of adjunctive CFAE ablation, we conducted a meta-analysis of all controlled trials comparing PVAI plus CFAE (CFAEs+PVAI) ablation with PVAI alone for the maintenance of sinus rhythm. Based on 7 controlled trials (9 comparisons) with a total of 622 participants, additional CFAE ablation was associated with significantly increased rates of sinus rhythm maintenance (relative risk, 1.17; 95% confidence interval, 1.03-1.33; P=0.019) at 12 months of follow-up. Subgroup analysis demonstrated that adjunctive CFAE ablation increased rates of sinus rhythm maintenance in nonparoxysmal AF (relative risk, 1.35; 95% confidence interval, 1.04-1.75; P=0.022) but had no effect on patients with paroxysmal AF. Compared with PVAI alone, PVAI followed by adjunctive CFAE ablation resulted in increased freedom from AF at 1 year. Intriguingly, results of the present meta-analysis suggest that only patients with nonparoxysmal AF gain additional benefit from the adjunctive CFAE ablation. Future research should concentrate on higher-quality and more rigorous randomized trials with longer follow-ups to further evaluate the clinical effectiveness and safety of additional CFAE ablation in patients with AF.
Conclusions-Adjuvant CFAE ablation in addition to standard PVAI increases the rate of long-term sinus rhythm maintenance in nonparoxysmal AF patients after a single procedure without antiarrhythmic drugs but does not provide additional benefit to sinus rhythm maintenance in paroxysmal AF patients. Summary-Atrial fibrillation (AF) imposes a symptomatic burden and the risk of cardiovascular events that increase in frequency with the progression of atrial electric and structural remodeling. The hypothesis that long-term renin-angiotensin system inhibition could reverse left atrial (LA) remodeling and thereby favor the prevention of AF recurrence was tested in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. The results revealed a neutral effect of valsartan treatment for 1 year on AF recurrence. The echocardiographic substudy results were consistent with those of the main study by showing valsartan to have no effect on LA volume. Severe LA enlargement (≥40 mL/m 2 ) recorded in 55% of the patients with only minimal increase in LV wall thickness and Doppler E/e′ argues for the arrhythmia itself as the main cause of LA remodeling. Additionally, in the patients without AF recurrence in 1 year, LA maximal volume was equally and severely dilated; therefore, mechanisms other than remodeling need consideration in future studies. Although LA maximal volume was not predictive of first recurrence of AF, in patients with recurrent AF (54%), larger LA volumes and lower LA emptying fraction did forecast longer episodes of AF recurrence. The entry of 85% hypertensive patients and only 10% with left ventricular dysfunction and heart failure emphasizes the causal role of blood pressure in AF. Aggressive treatment of blood pressure targeted to increasing LA volumes could slow and possibly halt progressive LA remodeling and prevent or reduce the burden of recurrent AF.
Conclusions-GISSI-AF patients in sinus rhythm and history of AF showed severely increased LAVmax with mostly normal LV volume, mass, and systolic and diastolic function. Valsartan for 1 year did not reverse LA remodeling or prevent AFr. Half of the patients without AFr had severe LA dilation; therefore, mechanisms other than structural remodeling triggered recurrence.
Nonetheless, repeat revascularization remains common after contemporary percutaneous coronary intervention (PCI). It remains unclear whether these repeat events represent TLR, staging of complex PCI procedures, or progressive atherosclerosis or unrecognized ischemia at previously untreated sites. In a large multicenter registry of contemporary PCI, repeat revascularization occurred in ≈12% of patients within 1 year. One fourth of these repeat procedures were staged or planned, generally occurring within the first 1 to 2 months after PCI, and there was significant variability in multivessel disease management between hospitals. The remaining 9% of repeat procedures were unplanned, with half involving TLR and half involving nontarget revascularization, and predictors of these 2 subgroups of repeat revascularization were remarkably different. The low early hazard for stent thrombosis decreases even further after the first month. These findings suggest that future efforts should concentrate as much on identifying ischemia-producing lesions and intensifying secondary prevention therapies as on the prevention of restenosis.
Conclusions-Among unselected patients undergoing PCI in the drug-eluting stent era, the incidence of repeat revascularization at 1 year is ≈12%. Among unplanned procedures, only half are performed for TLR. To achieve further improvements in PCI outcomes, future efforts should concentrate as much on identifying ischemiaproducing lesions and intensifying secondary prevention therapies as on the prevention of restenosis.
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The Quality and Impact of Risk Factor Control in Patients With Stable Claudication Presenting for Peripheral Vascular Interventions
Summary-Patients with peripheral vascular disease are at high risk for developing coronary and cerebrovascular disease. Risk factor modification with use of statins and aspirin has been shown to reduce major adverse cardiovascular events in patients with peripheral vascular disease. Risk factors are often under treated in patients with peripheral vascular diseases. Patients presenting for elective intervention for stable claudication often arrive on suboptimal medical therapy. Despite contact with a vascular specialist during the peripheral vascular intervention encounter patients are frequently discharged without statin therapy. Patients who present on a statin and aspirin before a peripheral vascular intervention have a lower odds of developing a peripheral vascular event in the six months after the intervention.
Conclusions-The fundamental elements of medical therapy in patients with lifestyle-limiting claudication are often underutilized before referral for revascularization. Appropriate medical therapy before percutaneous revascularization is associated with fewer peripheral vascular events at 6 months. 43 
Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy: Observations From the COURAGE Trial
Summary-Acute coronary syndromes are believed to arise commonly from lesions <50% diameter stenosis. Prognosis in patients with coronary disease is related to overall atherosclerosis burden. In patients treated with optimal medical therapy, symptoms that developed during follow-up were attributed to progression of lesions originally <50% diameter stenosis in one third of patients. Lesions <50% that progressed represented <4% of all such lesions. In patients treated with optimal medical therapy and percutaneous coronary intervention, lesions originally ≥50% diameter stenosis were responsible for new symptoms in 20% of patients and 68% in optimal medical therapy-only patients. The number of nonrevascularized lesions originally ≥50% diameter stenosis was the only angiographic predictor of myocardial infarction or acute coronary syndrome.
Conclusions-Lesions originally <50% diameter stenosis were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented <4% of all such lesions. Nonrevascularized lesions originally ≥50% DS were more often index lesions in OMT-only patients, but still represented a minority (<25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI. 44 
Stress Reduction in the Secondary Prevention of Cardiovascular Disease: Randomized, Controlled Trial of Transcendental Meditation and Health Education in Blacks
Summary-Psychosocial stress is associated with the onset and progression of cardiovascular disease in blacks and the general population. Stress reduction with the Transcendental Meditation program has previously been shown to beneficially affect cardiovascular risk factors, eg, hypertension, psychological stress, substance abuse, insulin resistance, myocardial ischemia, left ventricular mass and carotid atherosclerosis. This randomized, controlled trial found that adding stress-reducing Transcendental Meditation to usual care in patients with coronary heart disease resulted in a 48% reduction in the risk for cardiovascular clinical events, that is, mortality, myocardial infarction, and stroke during >5 years of follow-up. Potential mechanisms for the observed differences in survival include lower blood pressure and anger scores. There was evidence for dose-response effect between regularity of meditation practice and longer survival. The Transcendental Meditation program may be useful in the secondary prevention of cardiovascular disease.
Conclusions-A selected mind-body intervention, the Transcendental Meditation program, significantly reduced risk for mortality, myocardial infarction, and stroke in coronary heart disease patients. These changes were associated with lower blood pressure and psychosocial stress factors. Therefore, this practice may be clinically useful in the secondary prevention of cardiovascular disease. 45 
Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Summary-On the basis of the positive results of early trials, various clinical guidelines recommend the use of omega 3 fatty acid supplements to reduce mortality and cardiovascular risk. Several recent large trials have reported no benefit of omega 3 acids on cardiovascular outcomes; however, the recommendations for their use remain. This meta-analysis, which includes 20 trials and >60 000 patients, summarizes the entire body of evidence on this subject including all the recent trials. The results of this meta-analysis report that omega 3 fatty acids protect against vascular death, but there is no clear effect on total mortality, sudden death, stroke, or arrhythmia. The beneficial effects of omega 3 fatty acids are not as large as previously implied and recommendations for widespread use should be tempered.
Conclusions-Omega fatty acids may protect against vascular disease, but the evidence is not clear-cut, and any benefits are almost certainly not as great as previously believed. September 3, 2013
Left Ventricular Ejection Fraction Assessment Among Patients With Acute Myocardial Infarction and Its Association With Hospital Quality of Care and Evidence-Based Therapy Use
Summary-In patients with acute myocardial infarction, the appropriate medical regimen and subsequent management are dependent, in part, on residual left ventricular function. Therefore, assessment of left ventricular ejection fraction is a class I guideline recommendation for patients after an acute myocardial infarction. This analysis demonstrates overall high rates of left ventricular ejection fraction assessment in recent years; however, significant variability in assessment rate exists between hospitals. Importantly, hospitals with lower rates of left ventricular ejection fraction assessment are associated with lower quality of care for patients with acute myocardial infarction. Patient in whom left ventricular function is not assessed were less likely to receive evidence-based therapy and care.
Conclusions-The assessment of left ventricular ejection fraction (LVEF) among patients with acute myocardial infarction has improved significantly over time, yet significant interhospital variability exists. Patients who did not have in-hospital LVEF assessment were less likely to receive evidence-based medications at discharge. These patients represent targets for future quality improvement efforts. Summary-Reducing cardiovascular risk factors, including blood pressure and cholesterol, remains a critically important strategy for reducing the global burden of cardiovascular disease. A polypill combining generic hydrochlorothiazide (12.5 mg), atenolol (50 mg), ramipril (5 mg), simvastatin (20 mg), and aspirin (100 mg) has been shown to reduce blood pressure and cholesterol in patients with vascular disease. A randomized trial of providing 2 polypills to 257 subjects, along with potassium supplementation (30 mEq), resulted in further blood pressure reduction (mean systolic reduction of 2.8 mm Hg and diastolic reduction of 1.7 mm Hg; 95% CI, -0.17 to -2.8 mm Hg) and low-density lipoprotein cholesterol (adjusted difference, -7.2 mg/dL; 95% CI, -1.5 to -12.9 mg/dL), compared with a single polypill provided to 261 subjects. No significant difference in heart rate, high-density lipoprotein, or triglycerides was observed. The polypill regimens were similarly tolerated with 11.9% and 14% of the low-and high-dose groups stopping the study medication for some period during the 8 weeks of medication exposure.
Conclusions-The full-dose polycap (plus K + supplementation) reduces BP and low-density lipoprotein cholesterol to a greater extent compared with the low dose, with similar tolerability. Therefore, the full-dose polycap should potentially lead to larger benefits. 48 
